Shanghai United Pharmatech (UP) specializes in chemical synthesis of building blocks, pharmaceutical intermediates and active pharmaceutical ingredients (API) as well as pharmaceutical development of off-patent drugs. Based on the newly established laboratory in Zhangjiang Hi-tech Park, Shanghai and production site in Zhejiang province, we have built up a good relationship with many US / European / Japanese pharmaceutical companies to conduct chemical research?in medicinal chemistry and chemical process development of pharmaceutical intermediates, clinical APIs (FDA cGMP) and off-patented APIs (FDA cGMP & non-GMP). Our aim is to serve pharmaceutical community by providing excellent services and high-quality products in a timely manner.
United Pharmatech provides synthesis of libraries, building blocks, reference standards and impurities for US / European /Japanese pharmaceutical companies. Thousands of compounds have been prepared for our clients. The weight ranges from 50mg to 100g with 5 steps to 25 steps.
Full Time Equivalence (FTE)
United Pharmatech provides our clients FTE service at a very reasonable cost. Typically, a team led by experienced Ph.D. Chemists will be assigned to the clients based on its interview results and special requirements. Weekly reports and tele-conference are regularly used for project progress communication.
United Pharmatech has many advantages on chiral technology, including analytical methodology development, enzymatic and chemical resolutions and asymmetric synthesis. Currently, United Pharmatech has a focus on chiral amine product (see product) while providing service to our clients.
Process R&D is the strongest field in United Pharmatech. Many process chemists with US education background and US pharmaceutical experience are working for many different projects for US / European / Japanese clients based on projects or FTE.
Our kilo-lab is located at Shanghai, which is equipped with 20-50 liter glass flasks (25-300â„ƒ), jacked flasks (-70-0â„ƒ) and rotovapors. This kilo-lab provides a base for chemical development and allows us to scale up to 1-5 kilograms.
Our cGMP pilot plant in Zhejiang is equipped with reactors ranging from 50 liters to 500 liters, reaction temperature from -100â„ƒ to 300â„ƒ, hydrogenation pressure to 110 atm. Each process developed in our Shanghai lab will be transferred to the pilot plant by our R&D chemists and engineers. The pilot plant produces intermediates and APIs from kilograms to hundred kilograms.
Larger production request for United Pharmatech will be arranged to Lianhe Chemical Technology's production plants located in Huangyan, Zhejiang Province. The newly built plant is equipped with more than 150 reactors ranging from 1000 liters to 10,000 liters, reaction temperature from ?100? to 300?, hydrogenation processors up to 110 atm. The production plant provides a base for ton-scale production. Each process experienced in our pilot plant will be moved to the production plant by our R&D chemists and engineers upon larger production request. The plant produces intermediates and APIs from tons to thousand tons.
Chief Executive Officer
Xiongwei(Shawn) Shi, Ph.D.
Dr. Shi received his Ph.D. in Synthetic Organic Chemistry in 1993 from State University of New York. His major works included total syntheses of complex antitumoric Macbecin I and Herbimycin A, pine scale sex pheromones and methodology development of new [2,3]-Wittig rearrangements. Then he moved to Cornell University as a postdoctoral research associate in Synthetic Organic Chemistry with Professor Jerrold Meinwald, where he worked on stereo-controlled syntheses of cardiotonic and defensive steroids (Bufadienolides), defensive alkaloids and three sex pheromones( cockroach sex pheromones, longhorn beetle sex pheromone and stink bug sex pheromone). In 1996, Dr. Shi started his industrial career as a Senior Chemical Process Scientist in Sochering-Plough Research Institute. During the period of 1996-2003, Dr. Shi involved in many development projects to support phase I, II, III studies and commercial production of intermediates and APIs. These projects included new synthesis and process development of drug candidates for Alzheimer¡¯s disease (M2), Parkinsn¡¯s disease (AdA2) and AIDS disease (CCR5), anti-fungal and anticancer (FPTI) in cGMP environment. He has published more than 20 peer-reviewed papers in international journals and holds many patents.
Chemical Research Director
Dengfu Wang, Ph.D.
Mr. Wang received his BS degree of Chemistry in Jilin University in 1992 and MS degree in Wuhan University. He has over 5 years¡¯ experience in organic synthesis as a group leader in Chinese pharmaceutical company and moved to Astatech Inc. in NJ, USA. He spent more than four years there and made lots of contributions in custom synthesis. He has many papers published in major domestic and international chemistry journals.
Analytical Group Leader
Joey Zhan, M.D.
Mr. Zhan received his M. D. in 2002 from Shanghai Institute of Materia Medica, Chinese Academy of Sciences, majored in the Phytochemistry and Analytical Chemistry. After graduating from SIMM, he entered pharmaceutical industry as senior analyst. He has 6 papers published in international journal and applied a patent.
Zhangqiang Lu, MBA.
Mr. Lu received his MS. degree of mathematics in Xiamen University, he worked as an assistant of CEO in Wukuang Import & Export Corp., one of the largest Import & Export Companies in China. Mr. Lu moved to Ningbo and served as a general manager in a Financial Company in 1998, and moved to Shanghai in 2002 as a general manager in Import & Export Company before joining United Pharmatech.